Cardium Therapeutics (CXM)
Cardium Therapeutics R&D Expense: 1.165M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CXM R&D Expense Rankings
| Overall | 65th percentile | 600 of 1764 |
| Sector | 80th percentile | 82 of 413 in Healthcare |
| Industry | 87th percentile | 19 of 150 in Biotechnology |
CXM R&D Expense Range, Past 5 Years
| Minimum | 0.4427M | Dec 2010 |
| Maximum | 3.502M | Jun 2008 |
| Average | 1.441M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these CXM related companies
CXM News
$CXM Small Biotech Companies Look to Benefit From Improvement of U.S. Patent System http://stks.co/3yJh
about 4 days ago by OTCShowcase
about 4 days ago by OTCShowcase
Cardium Therapeutics (CXM) Enters Excellagen Agreement with Angel Biomedical
May 15, 9:09AM Street Insider
May 15, 9:09AM Street Insider
Cardium Presents First Quarter 2012 Financial Results and Recent Developments
May 15, 9:00AM PR Newswire
May 15, 9:00AM PR Newswire
$CXM Growing Footprint in Health Sciences and Regenerative Medicine Space http://stks.co/3nJI
about 17 days ago by MissionIR
about 17 days ago by MissionIR
Small Biotech Companies Look to Benefit From Improvement of U.S. Patent System
May 11, 8:20AM Marketwire
May 11, 8:20AM Marketwire
Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
Apr 19, 6:43PM PR Newswire
Apr 19, 6:43PM PR Newswire
Smith Medical Partners Announces Logistics Agreement for Cardium's National Distribution of Excellagen™
Apr 02, 8:00AM PR Newswire
Apr 02, 8:00AM PR Newswire
Cardium Presents Fourth Quarter and Year-End 2011 Financial Results and Recent Developments
Mar 30, 9:15AM PR Newswire
Mar 30, 9:15AM PR Newswire
FAST Act to Modernize Approval Process -- Cardium and BioSante Poised to Benefit
Mar 19, 8:20AM Marketwire
Mar 19, 8:20AM Marketwire
Cardium Presents New Generx Findings at 2012 Annual Gene and Cell Therapy Forum
Jan 30, 9:00AM PR Newswire
Jan 30, 9:00AM PR Newswire
Biotechnology Industry on the Upswing - BioSante and Cardium Therapeutics Look to Rally
Jan 17, 8:20AM Marketwire
Jan 17, 8:20AM Marketwire
Cardium Reports on Renewed Compliance With NYSE Amex Exchange Listing Guidelines
Jan 03, 9:01AM Benzinga
Jan 03, 9:01AM Benzinga
Cardium Therapeutics (CXM) Enters Into Cross-Strategic Equity Investment Partnership with SourceOne Global Partners
Dec 21, 9:23AM Street Insider
Dec 21, 9:23AM Street Insider
$CXM heavy premarket volume, potential FDA approval would be nice way to finish year
about 517 days ago by CaptainOyama
about 517 days ago by CaptainOyama
$SPY trending higher. Check out $CXM FDA approval coming 12/31 this stock trades at .48 will go to $2 or more on approval.
about 522 days ago by scottheggs
about 522 days ago by scottheggs
What to look forward to June 2010 for investors? $CXM, $HNAB, $DCTH, $QCOR http://goo.gl/fb/GuP5p #europecrisis
about 728 days ago by comparebroker
about 728 days ago by comparebroker
$CXM filled the gap.support at .58. first target .87, next stop 1.03. hope to see u all there.
about 766 days ago by StockTA888
about 766 days ago by StockTA888
but will consider buying in the .40s in $CXM, if it gets back down there.
about 768 days ago by LitheLyricist
about 768 days ago by LitheLyricist
buying programs chewing through offers in $CXM. A big offer is left at .55. Risk/reward not good enough to pay .55, probably
about 768 days ago by LitheLyricist
about 768 days ago by LitheLyricist
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CXM | 0.2375 | -0.00 | -0.25% | 28.41M |
| CXH | 10.60 | +0.00 | +0.00% | |
| CXDC | 4.93 | -0.05 | -1.00% | 234.32M |
| CXA | 24.42 | +0.02 | +0.08% | |
| CX | 5.47 | +0.00 | +0.00% | 5.797B |
| CWTR | 0.84 | +0.02 | +2.44% | 102.15M |
| CVS | 44.98 | -0.19 | -0.42% | 58.77B |
| CVRT | 21.71 | +0.00 | +0.00% | |
| CVR | 18.70 | -0.07 | -0.37% | 18.14M |
| CVO | 1.72 | +0.02 | +1.18% | 109.10M |
